Barclays Portfolio holdings
Barclays is a British universal bank whose roots go back to 1690, when the Quakers John Freame and Thomas Gould started a goldsmith banking business in London. The Barclays name came into the business in 1736, when James Barclay, son-in-law of founder John Freame, became a partner. Barclays launched the UK's first credit card, Barclaycard, in 1966, and in 1967 put the world's first cash machine in a branch in Enfield. In 2008 Barclays bought the North American operations of Lehman Brothers, and in 2009 it sold its Barclays Global Investors unit, home of the iShares ETFs, to BlackRock. It runs five divisions: UK consumer banking, UK corporate banking, private banking and wealth management, an investment bank and a US consumer bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$17.5B |
| 2 |
NVIDIA
NVDA
|
+$2.7B |
| 3 |
Intel
INTC
|
+$1.98B |
| 4 |
Broadcom
AVGO
|
+$1.46B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.11B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$35.8B |
| 2 |
Apple
AAPL
|
+$1.83B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$913M |
| 4 |
Microsoft
MSFT
|
+$856M |
| 5 |
Bank of America
BAC
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.47% |
| 2 | Technology | 19.84% |
| 3 | Consumer Discretionary | 7.61% |
| 4 | Financials | 5.61% |
| 5 | Communication Services | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3151
Flywire
FLYW
$2.77B
| $830K | ﹤0.01% |
47,438
+28,470
| +150% | +$508K |
2022 Q1
18 quarters
|
|
3152
Cadre Holdings
CDRE
$1.46B
| $828K | ﹤0.01% |
33,003
+8,417
| +34% | +$253K |
2022 Q1
18 quarters
|
|
3153
Viemed Healthcare
VMD
$346M
| $828K | ﹤0.01% |
90,968
+28,681
| +46% | +$290K |
2022 Q3
16 quarters
|
|
3154
PUT
Mirion Technologies
MIR
$4.35B
| $826K | ﹤0.01% |
+58,500
| New | +$925K |
2026 Q3
0 quarters
|
|
3155
Sutro Biopharma
STRO
$170M
| $823K | ﹤0.01% |
51,098
+14,144
| +38% | +$312K |
2026 Q1
2 quarters
|
|
3156
Blackstone Mortgage Trust
BXMT
$1.83B
| $823K | ﹤0.01% |
71,891
+39,341
| +121% | +$580K |
2014 Q2
49 quarters
|
|
3157
Firefly Aerospace
FLY
$4.45B
| $823K | ﹤0.01% |
35,552
-25,218
| -41% | -$575K |
2025 Q3
4 quarters
|
|
3158
CALL
Eos Energy Enterprises
EOSE
$729M
| $820K | ﹤0.01% |
267,500
-300,000
| -53% | -$1.17M |
2026 Q2
1 quarter
|
|
3159
Newsmax Inc
NMAX
$1000M
| $819K | ﹤0.01% |
75,744
+68,509
| +947% | +$659K |
2025 Q2
5 quarters
|
|
3160
Vanguard FTSE Developed Markets ETF
VEA
$231B
| $818K | ﹤0.01% |
11,583
-35,110
| -75% | -$2.52M |
2020 Q2
25 quarters
|
|
3161
Powell Industries
POWL
$5.32B
| $816K | ﹤0.01% |
4,423
-2,660
| -38% | -$546K |
2013 Q2
53 quarters
|
|
3162
Werner Enterprises
WERN
$1.67B
| $814K | ﹤0.01% |
23,965
-30,739
| -56% | -$1.2M |
2013 Q2
53 quarters
|
|
3163
Lumexa Imaging Holdings
LMRI
$1.53B
| $813K | ﹤0.01% |
79,330
+75,934
| +2,236% | +$863K |
2025 Q4
3 quarters
|
|
3164
Eton Pharmaceutcials
ETON
$1.97B
| $811K | ﹤0.01% |
15,746
-40,435
| -72% | -$2.05M |
2024 Q4
7 quarters
|
|
3165
MillerKnoll
MLKN
$1.5B
| $808K | ﹤0.01% |
41,123
+30,677
| +294% | +$675K |
2013 Q2
53 quarters
|
|
3166
Sixth Street Specialty
TSLX
$1.69B
| $808K | ﹤0.01% |
+44,837
| New | +$806K |
2026 Q3
0 quarters
|
|
3167
CALL
Camtek
CAMT
$5B
| $807K | ﹤0.01% |
+5,200
| New | +$764K |
2026 Q3
0 quarters
|
|
3168
Collegium Pharmaceutical
COLL
$771M
| $807K | ﹤0.01% |
36,987
-70,683
| -66% | -$2.06M |
2015 Q2
45 quarters
|
|
3169
Xerox
XRX
$135M
| $803K | ﹤0.01% |
253,733
+81,577
| +47% | +$249K |
2022 Q1
18 quarters
|
|
3170
SGHC Ltd
SGHC
$5.93B
| $802K | ﹤0.01% |
70,666
+44,867
| +174% | +$615K |
2022 Q4
15 quarters
|
|
3171
PDF Solutions
PDFS
$1.77B
| $801K | ﹤0.01% |
15,689
+3,264
| +26% | +$159K |
2016 Q2
41 quarters
|
|
3172
Douglas Emmett
DEI
$1.68B
| $800K | ﹤0.01% |
83,533
+39,225
| +89% | +$451K |
2013 Q2
53 quarters
|
|
|
MFP
3173
Midera Food Processing Inc
MFP
$2.06B
| $799K | ﹤0.01% |
+19,568
| New | +$876K |
2026 Q3
0 quarters
|
|
3174
nCino
NCNO
$2.37B
| $798K | ﹤0.01% |
44,022
+11,241
| +34% | +$221K |
2022 Q1
18 quarters
|
|
3175
Donegal Group Class A
DGICA
$709M
| $797K | ﹤0.01% |
44,811
+4,697
| +12% | +$88.8K |
2016 Q3
40 quarters
|
|
Similar funds
Barclays's Q3 2026 Portfolio in Review
As of Q3 2026, Barclays held 5,855 positions worth $500B, down 4% from $521B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays withdrew a net $19B in Q3 2026, closing 474 positions and reducing 1,494 holdings. Its most notable exit was ExxonMobil, an estimated $761M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 55% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares Broad USD High Yield Corporate Bond ETF worth $199M.
- Barclays's largest Q3 2026 buy was iShares Broad USD High Yield Corporate Bond ETF: 5,582,517 shares worth $199M.
- Barclays added most to Tesla in Q3 2026, an estimated $17.5B increase.
- Barclays's biggest Q3 2026 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $35.8B.
- Barclays fully exited ExxonMobil in Q3 2026, selling an estimated $761M.
- Barclays's ten largest holdings make up 40% of its $500B portfolio in Q3 2026.
- Barclays opened 525 new positions and closed 474 in Q3 2026.
- Barclays's portfolio value fell 4% quarter-over-quarter to $500B.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.